Cite
MLA Citation
Jianqiu Wu et al.. “Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study.” International journal of cancer, vol. 150, no. 6, 2022, pp. 984–992. http://access.bl.uk/ark:/81055/vdc_100148849939.0x00005f